Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Nucana Plc ADR (NCNA)

Nucana Plc ADR (NCNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis

Imbalances in Prognostic Factors May Have Impacted Analysis

NCNA : 8.00 (+9.29%)
NuCana Initiates Dosing in Phase I Study for Solid Tumors

NuCana (NCNA) doses the first patient in a phase I study on NUC-7738, which is being evaluated for the treatment of advanced solid tumors.

MRUS : 18.12 (-2.32%)
LLY : 111.01 (-1.35%)
RGEN : 92.15 (-1.55%)
NCNA : 8.00 (+9.29%)
NuCana Announces First Patients Dosed in Phase I Study of NUC-7738

NUC-7738 is NuCana's Third ProTide to Enter the Clinic

NCNA : 8.00 (+9.29%)
NuCana Reports First Quarter 2019 Financial Results and Provides Business Update

Numerous Clinical Data Announcements and Study Initiations Expected in 2019

NCNA : 8.00 (+9.29%)
NuCana to Participate in the William Blair 3rd Late-Stage Therapeutics Conference

NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Don Munoz, Chief Financial Officer,...

NCNA : 8.00 (+9.29%)
Will NuCana Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in NuCana.

NCNA : 8.00 (+9.29%)
NuCana Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Business Update

Numerous Clinical Data Announcements and Study Initiations Expected in 2019

NCNA : 8.00 (+9.29%)
NuCana to Present at the Cowen and Company 39th Annual Health Care Conference

NuCana plc (NASDAQ: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced today that Hugh Griffith, Chief Executive...

NCNA : 8.00 (+9.29%)
NuCana to Present at the American Association for Cancer Research (AACR) Annual Meeting 2019

NuCana plc (NASDAQ:NCNA) today announced that two abstracts related to NUC-3373 were selected for presentation at the AACR Annual Meeting 2019 to be held March 29 to April 3, 2019, in Atlanta, Georgia....

NCNA : 8.00 (+9.29%)
NuCana plc Announces Withdrawal of Public Offering of ADSs

EDINBURGH, United Kingdom, Jan. 25, 2019 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company (the "Company") focused on significantly improving treatment outcomes...

NCNA : 8.00 (+9.29%)
NuCana plc Announces Proposed Public Offering of ADSs

EDINBURGH, United Kingdom, Jan. 23, 2019 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with...

NCNA : 8.00 (+9.29%)
Amarin Down on Lower '19 View, Posts Preliminary '18 Results

Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.

AMRN : 15.43 (-1.47%)
MRUS : 18.12 (-2.32%)
NCNA : 8.00 (+9.29%)
MBRX : 1.15 (unch)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
AIZ -1.07 , WELL -0.87 , SBAC -0.79 , CCI -0.35 , SO -0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar